Castle Biosciences (NASDAQ:CSTL) specializes in developing and commercializing diagnostic and prognostic tests for cancers. They are devoted to transforming disease management through innovative molecular diagnostics that guide patient care. Their portfolio focuses chiefly on skin cancer, including melanoma, where they've made significant strides. Castle Biosciences aims to expand its impact by advancing the understanding of cancers at the genetic level, thus improving treatment decisions and outcomes for patients. Their objective is to lead in the realm of precision oncology, making personalized medicine more accessible and effective for cancer patients worldwide.